Navidea biopharmaceuticals, inc. drives strategy forward, shifts approach for communications

Dublin, ohio--(business wire)--navidea biopharmaceuticals, inc. (nyse american: navb) (“navidea” or the “company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced the introduction of a fix, fund, propel approach to driving the company's strategy forward; the company will issue a press release detailing financial highlights and corporate developments in lieu of hosting conference call and webcast for the first quarter ended march.
NAVB Ratings Summary
NAVB Quant Ranking